Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4024428 | 0.83 | NPC1 (0.43) | POLB | |
| SCHEMBL4030977 | 0.74 | EGFR (0.40) | POLB | |
| SCHEMBL8615413 | 0.73 | DPP7 (0.60) | KMT2ATLR2POLB | |
| Hydrochloric Acid SCHEMBL8615285 | 0.72 | DPP7 (0.59) | MEN1KMT2ATLR2POLB | |
| SCHEMBL5375489 | 0.72 | TLR2 (0.43) | CNR2MEN1KMT2ATLR2POLB | |
| SCHEMBL14861105 | 0.72 | CA12 (0.61) | KMT2APOLBHDAC8 | |
| SCHEMBL6961215 | 0.72 | CA12 (0.61) | KMT2APOLBHDAC8 | |
| SCHEMBL13073331 | 0.72 | CA12 (0.61) | KMT2APOLBHDAC8 | |
| SCHEMBL987969 | 0.71 | REN (0.60) | — | |
| SCHEMBL3409209 | 0.71 | REN (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244743-B2 | Non-peptidic BRS-3 agonists | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-07-17 | — | — | US | disclosed |
| US-20050171146-A1 | Non-peptidic BRS-3 agonists | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171146-A1 | Non-peptidic BRS-3 agonists | BRS3, NPR3, ADRB3 | CNR2 142/4885MEN1 738/4885KMT2A 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.